Reviva Pharmaceuticals Holdings, Inc.

NasdaqCM:RVPH Stock Report

Market Cap: US$85.4m

Reviva Pharmaceuticals Holdings Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Laxminarayan Bhat

Chief executive officer

US$2.6m

Total compensation

CEO salary percentage17.3%
CEO tenure17.9yrs
CEO ownership8.9%
Management average tenureno data
Board average tenure3.3yrs

Recent management updates

Recent updates

Here's Why Reviva Pharmaceuticals Holdings (NASDAQ:RVPH) Must Use Its Cash Wisely

Aug 24
Here's Why Reviva Pharmaceuticals Holdings (NASDAQ:RVPH) Must Use Its Cash Wisely

We're Keeping An Eye On Reviva Pharmaceuticals Holdings' (NASDAQ:RVPH) Cash Burn Rate

Dec 28
We're Keeping An Eye On Reviva Pharmaceuticals Holdings' (NASDAQ:RVPH) Cash Burn Rate

Reviva Pharmaceuticals drops 9% on $8.5M private placement

Sep 06

We're A Little Worried About Reviva Pharmaceuticals Holdings' (NASDAQ:RVPH) Cash Burn Rate

Aug 24
We're A Little Worried About Reviva Pharmaceuticals Holdings' (NASDAQ:RVPH) Cash Burn Rate

Reviva Pharmaceuticals Q2 GAAP loss per share widens

Aug 15

Reviva reports positive brilaroxazine results in Aacute Schizophrenia

Apr 26

CEO Compensation Analysis

How has Laxminarayan Bhat's remuneration changed compared to Reviva Pharmaceuticals Holdings's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023US$3mUS$450k

-US$39m

Sep 30 2023n/an/a

-US$38m

Jun 30 2023n/an/a

-US$31m

Mar 31 2023n/an/a

-US$24m

Dec 31 2022US$560kUS$400k

-US$28m

Sep 30 2022n/an/a

-US$20m

Jun 30 2022n/an/a

-US$19m

Mar 31 2022n/an/a

-US$15m

Dec 31 2021US$600kUS$400k

-US$9m

Sep 30 2021n/an/a

-US$6m

Jun 30 2021n/an/a

-US$5m

Mar 31 2021n/an/a

-US$4m

Dec 31 2020US$248kUS$248k

-US$4m

Sep 30 2020n/an/a

-US$2m

Jun 30 2020n/an/a

-US$2m

Mar 31 2020n/an/a

-US$1m

Dec 31 2019US$240kUS$240k

-US$847k

Dec 31 2018US$240kUS$240k

-US$2m

Compensation vs Market: Laxminarayan's total compensation ($USD2.61M) is above average for companies of similar size in the US market ($USD667.11K).

Compensation vs Earnings: Laxminarayan's compensation has increased whilst the company is unprofitable.

CEO

Laxminarayan Bhat (58 yo)

17.9yrs

Tenure

US$2,607,247

Compensation

Dr. Laxminarayan Bhat, Ph D., serves as the Founder of Reviva Pharmaceuticals Holdings, Inc. since 2006 and has been its Director since 2006 and serves as its President and Chief Executive Officer since Ma...

Board Members

NamePositionTenureCompensationOwnership
Laxminarayan Bhat
Founder18.3yrsUS$2.61m8.88%
$ 7.6m
Parag Saxena
Independent Chairman of the Board3.3yrsUS$107.01k3.12%
$ 2.7m
John Kane
Member of Advisory Boardno datano datano data
Daphne Karydas
Member of Advisory Boardno datano datano data
Les Funtleyder
Independent Director3.3yrsUS$88.01kno data
Richard Margolin
Independent Director3.3yrsUS$81.76kno data
Roham Zamanian
Member of Advisory Boardno datano datano data
Leslie Citrome
Member of Advisory Boardno datano datano data
Purav Patel
Independent Director6.9yrsUS$90.51k0.33%
$ 280.8k
Martin Kolb
Member of Advisory Boardno datano datano data

3.3yrs

Average Tenure

55yo

Average Age

Experienced Board: RVPH's board of directors are considered experienced (3.3 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.